Drug Profile
Dapaglifozin - Lyndra
Alternative Names: LYN‐045Latest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Lyndra
- Class Anti-ischaemics; Antihyperglycaemics; Antivirals; Benzhydryl compounds; Cardiovascular therapies; Chlorobenzenes; Glucosides; Heart failure therapies; Hepatoprotectants; Obesity therapies; Pyrans; Small molecules; Urologics
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders; Metabolic disorders; Type 2 diabetes mellitus
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (PO, Capsule)
- 28 Sep 2023 No recent reports of development identified for preclinical development in Metabolic-disorders in USA (PO, Capsule)
- 28 Jan 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Australia (PO, Capsule)